Influenza
Conditions
Keywords
Influenza, Virus, Vaccination, Immunisation
Brief summary
A study to evaluate the humoral immune response 3 weeks after vaccination with Inflexal V according to the CHMP criteria in elderly subjects for the 2011/2012 WHO recommended vaccine strains, to evaluate immunogenicity parameters 6 months after vaccination for the 3 vaccine strains and to assess the cross-protection against 4 selected circulating heterogeneous A/H1N1 influenza strains 3 weeks after influenza vaccination versus baseline.
Interventions
BIOLOGICALInflexal V
Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose: * 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus * 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus * 15 µg HA antigen of B/Brisbane/60/2008-like virus Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1
Sponsors
Crucell Holland BV
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy female and male adults aged \>60 years on the day of enrollment * Written informed consent * Females with confirmed menopause (postmenopausal is defined as 12 months with no menses without an alternative medical cause)
Exclusion criteria
* Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or other acute disease * Acute febrile illness (≥38.0 °C) * Prior vaccination with an influenza vaccine for season 2011/2012 * Known hypersensitivity to any vaccine component * Previous history of a serious adverse reaction to influenza vaccine * History of egg protein allergy or severe atopy * Known blood coagulation disorder * Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of the study vaccine, including oral corticosteroids in dosages of ≥0.5 mg/kg/day prednisolone or equivalent (inhaled or topical steroids are allowed) * Known immunodeficiency (including leukemia, HIV seropositivity) or cancer * Investigational medicinal product received in the past 3 months (90 days) * Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months (90 days) * Participation in another clinical trial * Employee at the investigational site or relative of the investigator * Anticipated non-compliance with study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Seroprotection | 3 weeks after vaccination (Day 22 ± 2 days) | Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40 (The primary endpoints are the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters will be analyzed according to the EMA Note for guidance on harmonisation of requirements for influenza vaccines, 1997) |
| Seroconversion | 3 weeks after vaccination (Day 22 ± 2 days) | Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40 (The primary endpoints are the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters will be analyzed according to the EMA Note for guidance on harmonisation of requirements for influenza vaccines, 1997) |
| Geometric Mean Titer | 3 weeks after vaccination (Day 22 ± 2 days) | GMT of HI antibodies and fold-increase in GMT (The primary endpoints are the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters will be analyzed according to the EMA Note for guidance on harmonisation of requirements for influenza vaccines, 1997) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titer | 6 months post-vaccination | GMT of HI antibodies and fold-increase in GMT (The primary endpoints are the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters will be analyzed according to the EMA Note for guidance on harmonisation of requirements for influenza vaccines, 1997) |
| Seroprotection | 6 months post-vaccination | Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40 (The primary endpoints are the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters will be analyzed according to the EMA Note for guidance on harmonisation of requirements for influenza vaccines, 1997) |
| Seroconversion | 6 months post-vaccination | Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40 (The primary endpoints are the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters will be analyzed according to the EMA Note for guidance on harmonisation of requirements for influenza vaccines, 1997) |
Countries
Italy
Outcome results
None listed